Related Experiment Video
Updated: Jul 18, 2026
07:59
Murine Full-thickness Skin Transplantation
Published on: January 2, 2017
Initial single-center experience with sirolimus after lung transplantation
R Lischke1, J Simonek, K Matousovic
13rd Department of Surgery, Thoracic and Lung Transplantation Division, University Hospital Motol, Prague, Czech Republic. robert.lischke@seznam.cz
Transplantation Proceedings
|November 23, 2006
Summary
Switching lung transplant patients from calcineurin inhibitors to sirolimus improved kidney function. This immunosuppressive therapy offers a viable alternative for managing renal impairment post-transplant.
Area of Science:
- Nephrology
- Transplantation Medicine
- Immunology
Background:
- Standard lung transplant immunosuppression involves calcineurin inhibitors, which can lead to chronic kidney disease.
- Sirolimus is explored as an alternative due to its lack of nephrotoxicity.
Purpose of the Study:
- To evaluate sirolimus as an alternative immunosuppressant in lung transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Main Methods:
- Prospective study switching 10 lung transplant recipients from tacrolimus to sirolimus.
- Dosing adjusted to maintain target trough levels; patients monitored for renal and graft function.
Main Results:
- Significant decrease in serum creatinine and azotemia observed after sirolimus initiation.
- Pulmonary function remained stable; seven infections and one death from bronchiolitis obliterans complications occurred.
Conclusions:
- Sirolimus is a beneficial alternative immunosuppressant for lung transplant recipients with renal impairment.
- Facilitates tacrolimus withdrawal and aids in the recovery of renal function.
